Capital Markets Day
hVIVO plc announced it will host a Capital Markets Day on June 11, 2026, to detail its evolution into an integrated early clinical development partner, moving beyond its leadership in human challenge trials. The event will feature client and expert speakers, including representatives from Boehringer Ingelheim and RA Capital, and will highlight case studies such as hVIVO's role in Cidara Therapeutics' $9 billion exit and ILiAD Biotechnologies' first Phase III human challenge trial. The company aims to demonstrate how its comprehensive platform accelerates drug development timelines and reduces execution risk for biotechnology and pharmaceutical clients.
Select text to share a quote on X · sign in to keep highlights & notes in your HVO notes
Speakers from Boehringer Ingelheim, RA Capital, ILiAD Biotechnologies and Decoy Therapeutics to discuss hVIVO's clinical development offering
London, UK - 20 May 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces that it will hold a Capital Markets Day for analysts, institutional investors and media in Canary Wharf on Thursday 11 June 2026 from 09:00 - 13:00 (BST).
The event will provide investors with a deeper understanding of hVIVO's strategic evolution from a specialist human challenge trial provider into a differentiated, integrated early clinical development partner, supporting biotechnology and pharmaceutical companies from preclinical strategy through first-in-human studies, patient trials and specialist laboratory services.
Through presentations from clients, investors, industry experts and hVIVO leadership, the event will explore how the Company's end-to-end platform is helping sponsors generate high-quality data earlier, accelerate development timelines and reduce execution risk across the clinical development pathway.
The programme will feature real-world case studies, including on hVIVO's role in supporting Cidara Therapeutics' drug development strategy leading to a $9 billion exit, and a presentation from ILiAD Biotechnologies on the world's first Phase III pivotal human challenge trial.
Discussions will also explore emerging investment trends in infectious disease, the strategic value of human challenge trials, the increasing importance of specialist partners in early drug development across Big Pharma and biotech, and how hVIVO's integrated platform supports faster, more informed development decisions.
External speakers will include:
- Mario Barro, PhD, Head of Infectious Diseases, RA Capital
- Stephanie Noviello, Chief Medical Officer, ILiAD Biotechnologies
- Corrina Pavetto, ClinReg Consulting, LLC (formerly SVP Clinical Development, Cidara Therapeutics)
- Konstantinos Sinogiannis, Global Category Manager, Boehringer Ingelheim
- Rick Pierce, Chief Executive Officer, Decoy Therapeutics
- Professor Richard Russell, Head of Immunobiology, Professor of Respiratory Medicine, King's College London
- Dr Diane Gbesemete, Clinical Research Fellow, University Hospital Southampton
The event will conclude with the opportunity for attendees to tour hVIVO's Canary Wharf quarantine facility and laboratories.
Analysts, institutional investors and media are welcome to attend the event in-person. Due to capacity constraints, attendance will be limited, however, a recording of the presentation will be made available on the Company's website shortly after the event.
To register your interest for the Capital Markets Day, please email hVIVO@icrhealthcare.com.
| Peel Hunt LLP (Joint Broker) | +44 (0)20 7418 8900 |
| James Steel, Dr Christopher Golden | |
| Davy (Joint Broker) | +353 (0) 1 679 6363 |
Anthony Farrell, Niall Gilchrist
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.